Contribution of retinoblastoma LOH and the p53 Arg/Pro polymorphism to cervical cancer

Molecular Medicine Reports

Volumn 6, Issue 3, 2012, Pages 473-476

  Eltahir, Huda A ^a   Elhassan, Ahmed M ^a   Ibrahim, Muntaser E ^a  

^a UNIVERSITY OF KHARTOUM   (Sudan)

Author keywords

Cervical cancer; Human papillomavirus; p53; Retinoblastoma gene; Sudan

Indexed keywords

ALLELE; ARTICLE; CANCER GROWTH; CANCER TISSUE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOSITY LOSS; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; INTRON; MAJOR CLINICAL STUDY; PATHOGENESIS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; WART VIRUS;

ADENOCARCINOMA; ALLELES; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INTRONS; LOSS OF HETEROZYGOSITY; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; RETINOBLASTOMA PROTEIN; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 84865166994     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.942     Document Type: Article

References (23)

1. Zur Hausen H: Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta 1288: 55-78, 1996.
2. Kloth JN, Kenter GG, Spijker HS, et al: Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival. Mod Pathol 21: 866-875, 2008. (Pubitemid 351896661)
3. Bookstein R and Allred DC: Recessive oncogenes. Cancer 71 (Suppl 3): S1179-S1186, 1993.
4. Kamil JP, Hume AJ, Jurak I, Münger K, Kalejta RF and Coena DM: Human papillomavirus 16 E7 inactivator of retinoblastoma family proteins complements human cytomegalovirus lacking UL97 protein kinase. Proc Natl Acad Sci USA 106: 16823-16828, 2009.
5. Heck DV, Yee CL, Howley PM and Münger K: Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci USA 89: 4442-4446, 1992.
6. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J and Crawford LV: Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7: 961-963, 1987. (Pubitemid 17004567)
7. Pim D and Banks L: p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108: 196-199, 2004. (Pubitemid 37541770)
8. Storey A, Thomas M, Kalita A, et al: Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393: 229-234, 1998. (Pubitemid 28261713)
9. Koushik A, Platt RW and Franco EL: p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev 13: 11-22, 2004. (Pubitemid 38116615)
10. Jee SH, Won SY, Yun JE, Lee JE, Park JS and Ji SS : Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis. Int J Gynaecol Obstet 85: 301-308, 2004. (Pubitemid 38622573)
11. Settheetham-Ishida W, Singto Y, Yuenyao P, Tassaneeyakul W, Kanjanavirojkul N and Ishida T: Contribution of epigenetic risk factors but not p53 codon 72 polymorphism to the development of cervical cancer in Northeastern Thailand. Cancer Lett 210: 205-211, 2004 (Pubitemid 38748691)
12. Lee SA, Kim JW, Roh JW, et al: Genetic polymorphisms of GSTM1, p21, p53 and HPV infection with cervical cancer in Korean women. Gynecol Oncol 93: 14-18, 2004. (Pubitemid 38429543)
13. Comar M, Molin GD, Guaschino S and Campello C: p53 at codon 72 polymorphism, human papillomavirus infection and cervical lesions: a cross-sectional study from northeastern Italy. Eur J Obstet Gynecol Reprod Biol 114: 210-214, 2004. (Pubitemid 38622084)
14. Ueda M, Hung YC, Terai Y, Saito J, Nunobiki O, Noda S and Ueki M: Glutathione-S-transferase and p53 polymorphisms in cervical carcinogenesis. Gynecol Oncol 96: 736-740, 2005. (Pubitemid 40255494)
15. Scambia G, Lovergine S and Masciullo V: RB family members as predictive and prognostic factors in human cancer. Oncogene 25: 5302-5308, 2006. (Pubitemid 44299091)
16. Soulitzis N, Sourvinos G, Sourvinos DN and Spandidos DA: P53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 179: 175-183, 2002. (Pubitemid 34215109)
17. Bereir RE, Mohamed HS, Seielstad M, et al: Allele frequency and genotype distribution of polymorphisms within disease-related genes is influenced by ethnic population sub-structuring in Sudan. Genetica 119: 57-63, 2003. (Pubitemid 36872727)
18. Zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350, 2002.
19. Smardová J, Nemajerová A, Trbusek M, Vagunda V and Kovarík J: Rare somatic p53 mutation identified in breast cancer: a case report. Tumor Biol 22: 59-66, 2001.
20. Zehbe I, Voglino G, Wilander E, et al: P53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res 61: 608-611, 2001. (Pubitemid 32128622)
21. Kim JW, Lee CG, Han SM, et al: Loss of heterozygosity of the retinoblastoma and p53 genes in primary cervical carcinomas with human papillomavirus infection. Gynecol Oncol 67: 215-221, 1997. (Pubitemid 27500423)
22. Park JS, Dong SM, Kim HS, et al: Detection of p16 gene alteration in cervical cancer using tissue microdissection and LOH study. Cancer Lett 136: 101-108, 1999. (Pubitemid 29142308)
23. Xing EP, Yang GY, Wang LD, Shi ST and Yang CS: Loss of heterozygosity of the Rb gene correlates with pRb protein expression and associates with p53 alteration in human esophageal cancer. Clin Cancer Res 5: 1231-1240, 1999. (Pubitemid 29233242)